Role of Aromatic Side Chains in Amyloid β-protein Aggregation

Overview

Journal ACS Chem Neurosci

Publisher American Chemical Society

Specialty Neurology

Date 2012 Dec 22

PMID 23259036

Citations 29

Authors

Risto Cukalevski

Barry Boland

Birgitta Frohm

Eva Thulin

Dominic Walsh

Sara Linse

Affiliations

Soon will be listed here.

Abstract

Aggregation of the amyloid β-protein (Aβ) is believed to be involved in Alzheimer's disease pathogenesis. Here we have investigated the importance of the aromatic rings at positions 19 and 20 for the aggregation rate and mechanism by substituting phenylalanine with leucine. Aggregation kinetics were monitored as a function of time and peptide concentration by thioflavin T (ThT) fluorescence, the aggregation equilibrium by sedimentation assay, structural changes using circular dichroism spectroscopy and the presence of fibrillar material was detected with cryo-transmission electron microscopy. All peptides convert from monomer to amyloid fibrils in a concentration-dependent manner. Substituting F19 with leucine results in a peptide that aggregates significantly slower than the wild type, while substitution of F20 produces a peptide that aggregates faster. The effects of the two substitutions are additive, since simultaneous substitution of F19 and F20 produces a peptide with aggregation kinetics intermediate between F19L and F20L. Our results suggest that the aromatic side-chain of F19 favors nucleation of the aggregation process and may be an important target for therapeutic intervention.

Citing Articles

catGRANULE 2.0: accurate predictions of liquid-liquid phase separating proteins at single amino acid resolution.

Monti M, Fiorentino J, Miltiadis-Vrachnos D, Bini G, Cotrufo T, Sanchez de Groot N Genome Biol. 2025; 26(1):33.

PMID: 39979996 PMC: 11843755. DOI: 10.1186/s13059-025-03497-7.

The Inhibition of Serum Amyloid A Protein Aggregation by a Five-Residue Peptidomimetic: Structural and Morphological Insights.

Witkowska J, Skibiszewska S, Wityk P, Pilarski M, Jankowska E Molecules. 2024; 29(21).

PMID: 39519806 PMC: 11547336. DOI: 10.3390/molecules29215165.

designed aliphatic and aromatic peptides assemble into amyloid-like cytotoxic supramolecular nanofibrils.

Samui S, Biswas S, Basak S, Ghosh S, Muniyappa K, Naskar J RSC Adv. 2024; 14(7):4382-4388.

PMID: 38304566 PMC: 10831423. DOI: 10.1039/d3ra07869h.

Amyloid β Proteoforms Elucidated by Quantitative LC/MS in the 5xFAD Mouse Model of Alzheimer's Disease.

Kandi S, Cline E, Rivera B, Viola K, Zhu J, Condello C J Proteome Res. 2023; 22(11):3475-3488.

PMID: 37847596 PMC: 10840081. DOI: 10.1021/acs.jproteome.3c00353.

Amyloid Fibrils of Stefin B Show Anisotropic Properties.

Zganec M, Taler Vercic A, Musevic I, Skarabot M, Zerovnik E Int J Mol Sci. 2023; 24(4).

PMID: 36835149 PMC: 9962164. DOI: 10.3390/ijms24043737.

References

Esler W, Stimson E, Ghilardi J, Lu Y, Felix A, Vinters H . Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence. Biochemistry. 1996; 35(44):13914-21. DOI: 10.1021/bi961302+. View

Chalifour R, McLaughlin R, Lavoie L, Morissette C, Tremblay N, Boule M . Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. J Biol Chem. 2003; 278(37):34874-81. DOI: 10.1074/jbc.M212694200. View

Wood S, Wetzel R, Martin J, Hurle M . Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochemistry. 1995; 34(3):724-30. DOI: 10.1021/bi00003a003. View

Gazit E . A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J. 2002; 16(1):77-83. DOI: 10.1096/fj.01-0442hyp. View

Selkoe D . The molecular pathology of Alzheimer's disease. Neuron. 1991; 6(4):487-98. DOI: 10.1016/0896-6273(91)90052-2. View

De Strooper B . Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev. 2010; 90(2):465-94. DOI: 10.1152/physrev.00023.2009. View

Petkova A, Yau W, Tycko R . Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry. 2006; 45(2):498-512. PMC: 1435828. DOI: 10.1021/bi051952q. View

Tew D, Bottomley S, Smith D, Ciccotosto G, Babon J, Hinds M . Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. Biophys J. 2007; 94(7):2752-66. PMC: 2267149. DOI: 10.1529/biophysj.107.119909. View

Selkoe D . The origins of Alzheimer disease: a is for amyloid. JAMA. 2000; 283(12):1615-7. DOI: 10.1001/jama.283.12.1615. View

10.

Paravastu A, Leapman R, Yau W, Tycko R . Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci U S A. 2008; 105(47):18349-54. PMC: 2587602. DOI: 10.1073/pnas.0806270105. View

11.

Lacor P, Buniel M, Furlow P, Clemente A, Velasco P, Wood M . Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007; 27(4):796-807. PMC: 6672917. DOI: 10.1523/JNEUROSCI.3501-06.2007. View

12.

Cohen S, Linse S, Luheshi L, Hellstrand E, White D, Rajah L . Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci U S A. 2013; 110(24):9758-63. PMC: 3683769. DOI: 10.1073/pnas.1218402110. View

13.

Scherzer-Attali R, Pellarin R, Convertino M, Frydman-Marom A, Egoz-Matia N, Peled S . Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS One. 2010; 5(6):e11101. PMC: 2885425. DOI: 10.1371/journal.pone.0011101. View

14.

Biancalana M, Koide S . Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta. 2010; 1804(7):1405-12. PMC: 2880406. DOI: 10.1016/j.bbapap.2010.04.001. View

15.

Hellstrand E, Boland B, Walsh D, Linse S . Amyloid β-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. ACS Chem Neurosci. 2012; 1(1):13-8. PMC: 3368626. DOI: 10.1021/cn900015v. View

16.

Qiu W, Folstein M . Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging. 2006; 27(2):190-8. DOI: 10.1016/j.neurobiolaging.2005.01.004. View

17.

Walsh D, Thulin E, Minogue A, Gustavsson N, Pang E, Teplow D . A facile method for expression and purification of the Alzheimer's disease-associated amyloid beta-peptide. FEBS J. 2009; 276(5):1266-81. PMC: 2702495. DOI: 10.1111/j.1742-4658.2008.06862.x. View

18.

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

19.

Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S . Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol. 2010; 17(5):561-7. PMC: 2922021. DOI: 10.1038/nsmb.1799. View

20.

Walsh D, Selkoe D . A beta oligomers - a decade of discovery. J Neurochem. 2007; 101(5):1172-84. DOI: 10.1111/j.1471-4159.2006.04426.x. View